Drugs / ATH-1105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06432647 | Apr → Nov 2024 | — | LeonaBio | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-11-06 | LeonaBio | Results Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update leonabio.com ↗
We were especially pleased to present results from the Phase 1 study of ATH-1105 that continue to demonstrate favorable safety and tolerability in healthy volunteers and dose proportional pharmacokinetics and CNS penetration. |
| 2025-08-14 | LeonaBio | Results Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 leonabio.com ↗
Results from the Phase 1 trial of ATH-1105 demonstrated a favorable safety and tolerability profile as well as dose-proportional pharmacokinetics and CNS penetration. |
| 2025-05-13 | LeonaBio | Results Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit leonabio.com ↗
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development |
| 2024-12-06 | LeonaBio | Results Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND leonabio.com ↗ |
| 2024-02-08 | LeonaBio | Results Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) leonabio.com ↗
These data demonstrate that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS. |
| 2023-10-05 | LeonaBio | Results Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) leonabio.com ↗
New results support the neuroprotective effects of ATH-1105 in preclinical models of ALS, as indicated by consistent reduction in plasma neurofilament light chain (NfL) levels and preservation of motor function |
| 2023-07-17 | LeonaBio | Results Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease leonabio.com ↗
In preclinical models, ATH-1105 protects against pathologies common to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) |
| 2023-04-25 | LeonaBio | Results Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting leonabio.com ↗
ATH-1105 significantly prolongs survival and improves motor function in a mouse model of ALS; strongly supports its potential for ALS |
| 2022-12-05 | LeonaBio | Results Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND leonabio.com ↗
The study results show that compared to untreated TDP-43 controls: ATH-1105-treated mice were protected against loss of body weight and had significant improvement in motor function and coordination, as assessed by balance beam cross times |
All press releases naming this drug 13 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATH-1105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06432647 ↗ |
| Route | Oral | “ATH-1105 in oral form.” NCT06432647 ↗ |